ABOUT BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH

BioXcellence Manufacturing - Tailored Capacities. Reliable Supply. Your Success, Our Commitment.

Boehringer Ingelheim BioXcellence™ is one of the leading biopharmaceutical contract manufacturers — a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation, streamlining your product's lifecycle.

We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, optimal preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals.

With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharmaceutical medicines to the market.,.

Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With more than 440 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients.

Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.

FEATURED INDUSTRY INSIGHTS

CONTACT INFORMATION

Boehringer Ingelheim Biopharmaceuticals GmbH

Binger Strasse 173

Ingelheim, 55216

GERMANY

Contact: Dr. Barbara Esch, Head of Marketing BioXcellence

FEATURED SOLUTIONS

  • Partner with a global network of cGMP-certified mammalian cell culture manufacturing facilities to ensure scalable, high-quality biologics production and seamless global supply.

  • This content was created by Boehringer Ingelheim BioXcellence™

    Among the constantly growing market of biopharmaceuticals, monoclonal antibodies derived from mammalian cell culture account for a share of approximately 50%.

  • Partner with Boehringer Ingelheim BioXcellence™ to leverage our world-class expertise and long-term commitment in advancing your product from concept to success.

  • Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.

  • Whether you are looking to optimize your existing formulations or require full-scale manufacturing solutions, Boehringer Ingelheim BioXcellence™ is dedicated to helping you realize your vision and deliver impactful therapies.

  • This content was created by Boehringer Ingelheim BioXcellence™

    Microbial product market is a market with attractive growth – and that growth is coming from diverse molecule formats and process formats where Boehringer Ingelheim in Vienna has outstanding development and manufacturing experience. We’re proud to be pioneers in the microbial field, with a track record of success going back to the 1980s and our work on recombinant interferons. Since then, we have brought 20 microbial manufactured products to the global market: some our own, some as trusted manufacturing partner.